Cerebral β-amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage

Annals of Neurology

Volumn 68, Issue 6, 2010, Pages 959-962

  Ly, John V ^a   Rowe, Christopher C ^b   Villemagne, Victor L ^b   Zavala, Jorge A ^a   Ma, Henry ^a   O'Keefe, Graeme ^b   Gong, Sylvia J ^b   Gunawan, Rico ^a   Churilov, Leonid ^a   Saunder, Tim ^b   Ackerman, Uwe ^b   Tochon Danguy, Henri ^b   Donnan, Geoffrey A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Forest Science Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; AMYLOID BETA PROTEIN; CARBON 11; PITTSBURGH COMPOUND B;

AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DRUG RETENTION; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; NEOCORTEX; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; VASCULAR AMYLOIDOSIS;

AGED; BENZOTHIAZOLES; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; ROC CURVE; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 78650872307     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22072     Document Type: Article

References (24)

1. McCarron MO, Nicoll JA,. Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol 2004; 3: 484-492.
2. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-234.
3. Ly JV, Donnan GA, Villemagne VL, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010; 74: 487-493.
4. Larrue V, von Kummer R, del Zoppo G, Bluhmki E,. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997; 28: 957-960.
5. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
6. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740-747.
7. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46: 1959-1972.
8. Jean WC, Spellman SR, Nussbaum ES, Low WC,. Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery 1998; 43: 1382-1396; discussion 1396-1397.
9. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28: 2109-2118.
10. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 1991; 83: 448-459.
11. Kase CS, O'Neal AM, Fisher M, et al. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Intern Med 1990; 112: 17-21.
12. Saver JL,. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke 2007; 38: 2279-2283.
13. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999; 30: 34-39.
14. Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002; 33: 717-724.
15. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002; 105: 1679-1685.
16. Palumbo V, Boulanger JM, Hill MD, et al. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007; 68: 1020-1024.
17. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
18. Thomalla G, Sobesky J, Kohrmann M, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 2007; 38: 313-318.
19. Rowe CC, Ng S, Ackermann U, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-1725.
20. Winkler DT, Biedermann L, Tolnay M, et al. Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. Ann Neurol 2002; 51: 790-793.
21. Tsuji K, Aoki T, Tejima E, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005; 36: 1954-1959.
22. Sumii T, Lo EH,. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33: 831-836.
23. Derex L, Hermier M, Adeleine P, et al. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry 2005; 76: 70-75.
24. Kandzari DE, Granger CB, Simoons ML, et al. Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). Am J Cardiol 2004; 93: 458-461.